The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Aug. 05, 2025

Filed:

Oct. 22, 2019
Applicant:

Fusion Antibodies Plc, Belfast Antrim, GB;

Inventors:

Richard Buick, Belfast Antrim, GB;

Christopher Scott, Belfast Antrim, GB;

Darragh Maccann, Belfast Antrim, GB;

Leona Mcgirr, Belfast Antrim, GB;

Hugh Morgan, Belfast Antrim, GB;

Natasha Campbell, Belfast Antrim, GB;

James Mcclory, Belfast Antrim, GB;

Anthony O'kane, Belfast Antrim, GB;

Assignee:

Fusion Antibodies PLC, Belfast Antrim, GB;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C40B 50/06 (2006.01); C07K 16/00 (2006.01); C07K 16/32 (2006.01); C07K 16/40 (2006.01); C12N 15/10 (2006.01);
U.S. Cl.
CPC ...
C40B 50/06 (2013.01); C07K 16/005 (2013.01); C07K 16/32 (2013.01); C07K 16/40 (2013.01); C12N 15/1089 (2013.01); C07K 2317/10 (2013.01); C07K 2317/565 (2013.01);
Abstract

This disclosure relates to methods of generating antibody libraries, antibody libraries produced using such methods, and variant antibodies. Presently, methods of improving antibody binding (affinity maturation assays) require the screening of vast libraries of antibody variants (often >10) to identify a small fraction of variants with improved characteristics. The present invention involves taking the nucleotide sequence of the framework and complementarity determining region of a target antibody and identifying motifs which would be recognised by deamination somatic hypermutation enzymes. A small library of variants is then created which incorporate one or more of these mutations. It was found that a relatively high proportion of the variants have an increased affinity. The technique of the present invention was demonstrated on the trastuzumab and Cathepsin S antibodies, and the variants produced are also claimed.


Find Patent Forward Citations

Loading…